<DOC>
	<DOCNO>NCT00484211</DOCNO>
	<brief_summary>The main objective trial document progression free survival ( PFS ) advance metastatic hepatocellular carcinoma patient treat NGR-hTNF single agent . Safety establish clinical laboratory assessment accord NCI-CTC criterion</brief_summary>
	<brief_title>Study NGR-hTNF Single Agent Patients Affected Advanced Metastatic Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description>This phase II , open-label , non-randomized study conduct patient affect advanced metastatic Hepatocellular Carcinoma ( HCC ) previously treat one systemic therapeutic regimen , conduct use Simon 's two-stage design method .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Patients &gt; 18 year affect advanced metastatic HCC previously treat one systemic therapeutic regimen Histologically confirm HCC amenable curative surgery ChildPugh scale class A ECOG Performance status 0 1 Patients progression disease study entry CT document Adequate baseline bone marrow , hepatic renal function , define follow : Neutrophils &gt; 1.5 x 10^9/L platelet &gt; 100 x 10^9/L Bilirubin &lt; 2 x ULN Transaminases &lt; 3 x ULN Absence condition hypervolaemia consequence ( e.g . increase stroke volume , elevate blood pressure ) haemodilution could represent risk patient ( reference appendix `` Technical data sheet human albumin '' ) Normal cardiac function absence uncontrolled hypertension Patients must give write informed consent Exclusion criterion : Decompensated cirrhosis ( ChildPugh score &gt; 7 ) Concurrent anticancer therapy Patients may receive investigational agent study Clinical sign CNS involvement Patients active uncontrolled systemic disease/infections serious illness medical condition , incompatible protocol Known hypersensitivity/allergic reaction human albumin preparation excipients Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol Pregnancy lactation . Patients male female reproductive potential ( i.e . menopausal le 1year surgically sterilize ) must practice effective contraceptive measure throughout study . Women childbearing potential must provide negative pregnancy test ( serum urine ) within 14 day prior registration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>NGR-hTNF , Hepatocellular Carcinoma ( HCC )</keyword>
</DOC>